{"id":"bucillamine","rwe":[{"pmid":"41635385","year":"2026","title":"Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41579307","year":"2026","title":"A case of bucillamine-induced membranous nephropathy presenting with acute kidney injury and requiring hemodialysis.","finding":"","journal":"CEN case reports","studyType":"Clinical Study"},{"pmid":"41572965","year":"2026","title":"Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation.","finding":"","journal":"International journal of rheumatic diseases","studyType":"Clinical Study"},{"pmid":"41269131","year":"2026","title":"High MDR1 expression in RA is associated with increased MMP-3 levels and use of bDMARDs: potential independence of JAK inhibitors from MDR1.","finding":"","journal":"Rheumatology (Oxford, England)","studyType":"Clinical Study"},{"pmid":"40793958","year":"2025","title":"Drug Repurposing Patent Applications January-March 2025.","finding":"","journal":"Assay and drug development technologies","studyType":"Clinical Study"}],"tags":[{"label":"bucillamine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"M01CC02","category":"atc"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antioxidants","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":130.514,"date":"","count":26,"signal":"Lymphoproliferative disorder","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=131)"},{"llr":97.969,"date":"","count":40,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=98)"},{"llr":58.364,"date":"","count":16,"signal":"Diffuse large B-cell lymphoma","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=58)"},{"llr":49.785,"date":"","count":11,"signal":"Epstein-Barr virus associated lymphoproliferative disorder","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=50)"},{"llr":47.734,"date":"","count":14,"signal":"Epstein-Barr virus infection","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=48)"},{"llr":43.785,"date":"","count":16,"signal":"Pneumocystis jirovecii pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=44)"}],"commonSideEffects":[{"effect":"Lymphoproliferative disorder","drugRate":"LLR 131","severity":"common"},{"effect":"Interstitial lung disease","drugRate":"LLR 98","severity":"common"},{"effect":"Diffuse large B-cell lymphoma","drugRate":"LLR 58","severity":"common"},{"effect":"Epstein-Barr virus infection","drugRate":"LLR 48","severity":"common"},{"effect":"Pneumocystis jirovecii pneumonia","drugRate":"LLR 44","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"rimatil","offLabel":[],"synonyms":["bucillamine","rimatil","thiobutarit","tiobutarit"],"timeline":[],"aiSummary":"Rimatil, also known as bucillamine, is a small molecule drug in the bucillamine class. It is a copper-chelating agent that works by binding to copper ions in the body, which can help to reduce inflammation and oxidative stress. Bucillamine is used to treat rheumatoid arthritis, a chronic autoimmune disorder that causes inflammation and pain in the joints. The commercial status of bucillamine is not specified, but it is likely to be patented or have limited generic availability. As a copper-chelating agent, bucillamine may have interactions with other medications that also affect copper levels in the body.","brandName":"Rimatil","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bucillamine","explanation":"Think of copper as a spark that can ignite a fire of inflammation in the body. Bucillamine is like a fire extinguisher that puts out that spark by binding to the copper and preventing it from causing damage. This helps to reduce pain and inflammation in people with rheumatoid arthritis.","oneSentence":"Bucillamine works by binding to copper ions in the body, reducing inflammation and oxidative stress.","technicalDetail":"Bucillamine is a thiol-containing compound that acts as a copper chelator, binding to copper ions through the formation of a stable copper-thiolate complex. This complex is then excreted from the body, reducing the levels of free copper ions that can contribute to inflammation and oxidative stress."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/414","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BUCILLAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUCILLAMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:04:17.654325","biosimilars":[],"competitors":[{"drugName":"penicillamine","drugSlug":"penicillamine","fdaApproval":"1970-12-04","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"bucillamine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"penicillamine","brandName":"penicillamine","genericName":"penicillamine","approvalYear":"1970","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":["Rheumatoid Arthritis (RA)"],"enrollment":385,"completionDate":"2021-11-02"},{"nctId":"NCT04504734","phase":"PHASE3","title":"Bucillamine in Treatment of Patients With COVID-19","status":"TERMINATED","sponsor":"Revive Therapeutics, Ltd.","startDate":"2020-11-27","conditions":["Covid19"],"enrollment":713,"completionDate":"2023-06-12"},{"nctId":"NCT02373202","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-02","conditions":["Rheumatoid Arthritis"],"enrollment":91,"completionDate":"2016-11"},{"nctId":"NCT02942420","phase":"PHASE2","title":"Bucillamine Phase 2 Trial in Patients With Cystinuria","status":"UNKNOWN","sponsor":"Revive Therapeutics, Ltd.","startDate":"2017-05-01","conditions":["Cystinuria"],"enrollment":30,"completionDate":"2018-03"},{"nctId":"NCT02330796","phase":"PHASE2","title":"Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout","status":"COMPLETED","sponsor":"Revive Therapeutics, Ltd.","startDate":"2015-04","conditions":["Gout"],"enrollment":66,"completionDate":"2015-11"},{"nctId":"NCT00716248","phase":"PHASE4","title":"Bucillamine Study of Holding Remission After Infliximab Dose-off","status":"UNKNOWN","sponsor":"Saitama Medical University","startDate":"2007-01","conditions":["Rheumatoid Arthritis"],"enrollment":40,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"R80LRA5WTF","CHEBI":"CHEBI:31312","INN_ID":"5683","UMLSCUI":"C0073917","ChEMBL_ID":"CHEMBL80830","KEGG_DRUG":"D01809","DRUGBANK_ID":"DB12160","PUBCHEM_CID":"656604","MESH_SUPPLEMENTAL_RECORD_UI":"C026535"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":235,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01CC02","allCodes":["M01CC02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan","pmid":"41635385","title":"Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report.","journal":"Cureus"},{"date":"2026 Jan 24","pmid":"41579307","title":"A case of bucillamine-induced membranous nephropathy presenting with acute kidney injury and requiring hemodialysis.","journal":"CEN case reports"},{"date":"2026 Jan","pmid":"41572965","title":"Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation.","journal":"International journal of rheumatic diseases"},{"date":"2026 Feb 4","pmid":"41269131","title":"High MDR1 expression in RA is associated with increased MMP-3 levels and use of bDMARDs: potential independence of JAK inhibitors from MDR1.","journal":"Rheumatology (Oxford, England)"},{"date":"2025 Oct","pmid":"40793958","title":"Drug Repurposing Patent Applications January-March 2025.","journal":"Assay and drug development technologies"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}